Samsara BioCapital, L.P.

CIK 1699737 · last filed 2026-02-17

Samsara BioCapital, L.P. is a corporate insider who has filed 10 SEC Form 4 insider transactions across 5 companies since 2021. The most recent filing shows the insider bought $25.0M of KLRS on Feb 17, 2026. Across all open-market trades the lifetime net is +$91.8M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $222.6M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$222.59M

Companies

5

Total Filings

10

Lifetime Open-Market Net

$91.78M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
KLRS	10%+ Owner	1,979,847	$4.19	$8.30M	$25.00M	1	2026-02-17
MLYS	10%+ Owner	5,674,916	$26.99	$153.17M	$16.20M	1	2025-03-17
NGNE	10%+ Owner	1,717,127	$35.60	$61.13M	$3.78M	1	2024-11-27
CARGO Therapeutics, Inc. (CRGX) Delisted	10%+ Owner	4,121,689	$4.47	$18.42M	$30.00M	1	2023-11-16
LENZ Therapeutics, Inc. (GRPH) Delisted	10%+ Owner	1,208,473	$22.26	$26.90M	$16.81M	6	2022-04-13

Recent Filings

10 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2026-02-17	KLRS	Buy (P)	+2,399,235	$25.00M	EDGAR
2025-03-17	MLYS	Buy (P)	+1,200,000	$16.20M	EDGAR
2024-11-27	NGNE	Buy (P)	+146,310	$3.78M	EDGAR
2023-11-16	CARGO Therapeutics, Inc. (CRGX) Delisted	Mixed	+12,143,967	$30.00M	EDGAR
2022-04-13	LENZ Therapeutics, Inc. (GRPH) Delisted	Buy (P)	+848,928	$3.46M	EDGAR
2022-01-25	LENZ Therapeutics, Inc. (GRPH) Delisted	Buy (P)	+246,000	$2.20M	EDGAR
2022-01-21	LENZ Therapeutics, Inc. (GRPH) Delisted	Buy (P)	+195,340	$1.78M	EDGAR
2021-11-24	LENZ Therapeutics, Inc. (GRPH) Delisted	Buy (P)	+403,370	$4.09M	EDGAR
2021-10-15	LENZ Therapeutics, Inc. (GRPH) Delisted	Buy (P)	+101,600	$1.34M	EDGAR
2021-10-08	LENZ Therapeutics, Inc. (GRPH) Delisted	Buy (P)	+290,992	$3.94M	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.